MicrofluidX welcomes new board members and scientific advisor

MicrofluidX, a UK-based developer of technologies that streamline the development and deployment of cell and gene therapies, today announces the appointment of two new board members and an additional scientific advisor to support the company as it progresses towards market launch of its unified development and manufacturing platform, the Cyto EngineTM

The addition of these three distinguished leaders in their respective fields, brings a wealth of expertise to the MicrofluidX team, providing insight into the needs of cell and gene therapy manufacturers as well as extensive experience in the development of innovative tools and technologies to help meet the needs of this rapidly growing sector.

The company welcomes:

Tim Fell - Chair
With a 30+ year career in life sciences technology innovation Tim assumes the role of Board Chair. His proven track record in converting innovation into products and building early stage companies into successful commercial organizations will be instrumental in supporting MicrofluidX through its next phase of technology development and commercialization.

Joseph Gentile - Non-Executive Director
Joseph’s wealth of experience building innovative tools and technology companies in the cell and gene therapy and life sciences sectors provides a tremendous addition to the MicrofluidX board. Based in the US, his support, strategic direction, and guidance in this high-value region will be invaluable as the technology progresses to market entry.

Steven A Feldman - Scientific Advisor
As Site Head and Scientific Director for Stanford’s Laboratory for Cell and Gene Medicine and its GMP Manufacturing Facility, Steven is an internationally recognized expert in the development of cell and gene therapies. As a Scientific Advisor, he will provide key guidance in developing and refining the company's cutting-edge technologies.

CEO of MicrofluidX Antoine Espinet says “We are immensely proud to welcome Tim, Joseph and Steven to the MicrofluidX team. Their experience and insights into developing technologies and building companies, as well as the needs of the Cell and Gene Therapy community will be invaluable as we take the Cyto EngineTM from prototype to product.”


More news and updates 

Hartmut van Lengerich appointed as Chairman of Moa Technology

With over 30 years’ experience in global strategic and operational roles, including serving as Bayer Crop Science’s CEO for Canada, Global Head of Cereals, Head of Fungicides and, most recently, SVP Global Crop Protection Asset Management at Bayer AG, overseeing $13bn in worldwide sales

ACROBiosystems launches the world’s first GMP-grade DLL-4 Protein

ACROBiosystems, a global cornerstone of the pharmaceutical industry committed to offering innovative tools and solutions, announces the launch of GMP grade DLL4. GMP grade DLL4 is the first recombinant Delta-like Ligand 4, or DLL4, to be launched on the market under GMP conditions.

Investors-in-residence join Cancer Research Horizons to advance Ventures team

Jonathan Tobin, a partner at life science venture capital firm Brandon Capital, and Genghis Lloyd-Harris, a senior advisor at life sciences investment firm, Abingworth, have joined Cancer Research Horizons’ Ventures team as advisory investors-in-residence.

Milner, AstraZeneca, and MRC partner for functional genomics advancements

The University of Cambridge announced a new partnership with AstraZeneca and the Medical Research Council (MRC) that will establish a new state-of-the-art functional genomics laboratory at the Milner Therapeutics Institute.

RoslinCT to manufacture world’s-first CRISPR-based therapy

RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration

Rosalind Franklin Institute appoints Professor Paul Matthews as new director

The Rosalind Franklin Institute announces Professor Paul Matthews as its new Institute Director. Professor Matthews is a world class clinician scientist with over 30 years of experience working on neurodegenerative disorders.

Brainomix expands to the US with FDA-cleared Stroke AI Platform

Brainomix, the AI-powered medtech solutions company, has heralded its continued US expansion with the launch of its full suite of FDA-cleared modules in its Brainomix 360 platform for stroke care.

Cancer Research Horizons opens nominations for its Innovation & Entrepreneurship Awards 2024

Cancer Research Horizons, the innovation arm of Cancer Research UK, has opened nominations for its Innovation & Entrepreneurship Awards 2024, which celebrate the UK’s most enterprising efforts in oncology.

Merit reaches key project milestone for Moderna's clinical laboratories

Northumberland-headquartered Merit, the UK’s leading industrialised construction and digital manufacturing specialist, has reached a significant project milestone for Moderna’s clinical laboratories project.

PrecisionLife announces new appointments to launch diagnostics and healthcare strategy

PrecisionLife® announces the appointment of Dr Gerald Dunstan as SVP Corporate Development and Hannah Bibby as Product Strategy Lead to drive the company’s expansion into precision diagnostics and personalized healthcare.


More within